The world's first ALL CAR-T cell therapy!

Gilead's T cell therapy company Kite recently announced that the U.

It is worth mentioning that Tecartus is the first and only CAR-T cell therapy approved to treat ALL adults (≥18 years of age)

Since half of B-ALL patients will relapse when they are treated with currently available therapies, there is a very high unmet medical need in this field

This approval is based on the results of the ZUMA-3 test

T cell therapy is a promising treatment method

Tecartus received accelerated approval from the US FDA in July 2020 for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) adults who had previously received 2 or more systemic therapies (including a BTK inhibitor) Patient

The principle of Yescarta, Kymriah, and Tecartus is to genetically modify the patient’s own T cells to express a chimeric antigen receptor (CAR) that targets the antigen CD19, which is an antigen protein expressed on the surface of a variety of hematological tumor cells , Including B-cell lymphoma and leukemia cells

Tecartus is an autologous, anti-CD19, CAR-T cell therapy that uses the XLP manufacturing process, including T cell screening and lymphocyte enrichment

Acute lymphocytic leukemia (ALL) is an aggressive blood cancer that can also affect the lymph nodes, spleen, liver, central nervous system, and other organs

Note: The original text has been deleted

Original source: US FDA Approves Kite's Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia